{
    "criteria": [
        {
            "criterion": "AllDocuments",
            "passed": true,
            "reason": "All documents pass."
        },
        {
            "criterion": "QuestionAnswerStringsV2",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "FullyStructured",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamStringsV2",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamplesStrings",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamplesStringsV2",
            "passed": true,
            "reason": "Text contains This includes."
        },
        {
            "criterion": "ListPrefixV2",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamplesMinimalEmbed",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamplesSynonymsEmbed",
            "passed": false,
            "reason": "Does not meet criterion."
        },
        {
            "criterion": "ExamplesDiverseEmbed",
            "passed": false,
            "reason": "Does not meet criterion."
        }
    ],
    "doc_id": "708",
    "text": "AstraZeneca has bought the rights to an experimental kidney drug \u2013 the first major deal for the company since Pascal Soriot became CEO. A deal was expected following Pascal\u2019s suspension of AZ\u2019s share buybacks for the rest of the year on his first day in the job.\nAZ will pay US $35 million up front to biotech firm, Ardelyx, for a worldwide exclusive licensing agreement for Ardelyx\u2019s NHE3 inhibitor programme. This includes the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD).\nGunnar Olsson, Vice President and Head of CVGI Innovative Medicines, AstraZeneca.\nUnder further terms of the agreement, AZ will pay development milestone payments of US $237.5 million, as well as milestone payments related to launch and commercialisation and tiered, double-digit royalties. AZ will pay the development costs and Ardelyx will conduct Phase 2 clinical trials. As part of the transaction, Ardelyx has secured an option to co-promote the product in the US, subject to agreed limitations."
}